| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CHP |
| Uniprot No | Q99653 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-195aa |
| 氨基酸序列 | MGSRASTLLRDEELEEIKKETGFSHSQITRLYSRFTSLDKGENGTLSREDFQRIPELAINPLGDRIINAFFPEGEDQVNFRGFMRTLAHFRPIEDNEKSKDVNGPEPLNSRSNKLHFAFRLYDLDKDEKISRDELLQVLRMMVGVNISDEQLGSIADRTIQEADQDGDSAISFTEFVKVLEKVDVEQKMSIRFLH |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下为3篇关于CHP重组蛋白的示例参考文献(注：文献信息为模拟生成，实际引用请查询权威数据库)：
---
1. **文献名称**: *"Structural analysis of CHP1-reconstituted NHE1 complex reveals pH-sensitive regulatory mechanism"*
**作者**: Yamamoto K. et al. (2018)
**摘要**: 通过X射线晶体学解析CHP1重组蛋白与Na+/H+交换体NHE1的复合物结构，揭示CHP1依赖pH变化的构象变化如何调控离子转运活性。
2. **文献名称**: *"CHP2 overexpression promotes tumor metastasis via ERK signaling in breast cancer cells"*
**作者**: Li S. et al. (2020)
**摘要**: 研究重组CHP2蛋白在乳腺癌细胞中的功能，发现其通过激活ERK通路增强细胞迁移和侵袭，提示CHP2作为癌症治疗潜在靶点。
3. **文献名称**: *"Efficient expression and purification of recombinant CHP3 in E. coli for functional studies"*
**作者**: Gupta R. & Patel A. (2019)
**摘要**: 报道一种利用大肠杆菌高效表达并纯化CHP3重组蛋白的方法，优化条件后获得高纯度蛋白，适用于体外结合实验和抗体开发。
---
建议通过 **PubMed** 或 **Web of Science** 输入关键词 "CHP recombinant protein" 或 "Calcineurin Homologous Protein expression" 查询真实文献。
**Background of CHP Recombinant Proteins**
CHP (Calcium-binding protein 1 or CSE1L) recombinant proteins are engineered versions of the naturally occurring CHP family of proteins, which play critical roles in calcium signaling, cellular homeostasis, and intracellular trafficking. CHP proteins, including isoforms like CHP1. CHP2. and CHP3. are characterized by their EF-hand calcium-binding motifs, enabling them to regulate calcium-dependent processes such as membrane trafficking, ion transport, and cell survival. Dysregulation of CHP proteins has been implicated in diseases like cancer, neurodegenerative disorders, and cardiovascular conditions, driving interest in their study and therapeutic targeting.
Recombinant CHP proteins are produced via genetic engineering, where the CHP gene is cloned into expression vectors and expressed in host systems (e.g., *E. coli*, yeast, or mammalian cells*). This allows large-scale production of purified, functional CHP proteins for research and clinical applications. Recombinant technology enables customization, such as tagging for detection (e.g., His-tag, GFP) or site-specific mutations to study structure-function relationships.
In research, CHP recombinant proteins are used to investigate calcium signaling pathways, protein-protein interactions (e.g., with Na+/H+ exchangers or kinases), and their roles in apoptosis or autophagy. Therapeutically, they serve as tools for drug screening, antibody development, or potential biologics to modulate calcium-related pathologies. Challenges include maintaining post-translational modifications (e.g., phosphorylation) critical for activity, which often necessitates mammalian expression systems.
Overall, CHP recombinant proteins bridge basic science and translational medicine, offering insights into cellular mechanisms and avenues for therapeutic innovation. Their utility continues to expand with advances in protein engineering and biomanufacturing.
×
